Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

Diagnosing the Sweet syndrome

P R Cohen, R Kurzrock

Annals of Internal Medicine

|April 1, 1989

Summary

No abstract available in PubMed .

Related Concept Videos

You might also read

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

ESMO open·2026

Same author

Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.

ESMO open·2026

Same author

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

ESMO open·2025

Same author

The best management for most patients with incurable cancer is on a clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Related Experiment Videos

Diagnosing the Sweet syndrome

Related Concept Videos

Related Articles

Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward.

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

The best management for most patients with incurable cancer is on a clinical trial.